FR2875680A1 - Compose dietetique pour combattre le syndrome metabolique - Google Patents
Compose dietetique pour combattre le syndrome metabolique Download PDFInfo
- Publication number
- FR2875680A1 FR2875680A1 FR0410312A FR0410312A FR2875680A1 FR 2875680 A1 FR2875680 A1 FR 2875680A1 FR 0410312 A FR0410312 A FR 0410312A FR 0410312 A FR0410312 A FR 0410312A FR 2875680 A1 FR2875680 A1 FR 2875680A1
- Authority
- FR
- France
- Prior art keywords
- histidine
- tryptophan
- egg
- metabolic syndrome
- lactoserum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 title claims abstract description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title claims abstract description 5
- 102000004407 Lactalbumin Human genes 0.000 title claims abstract description 4
- 108090000942 Lactalbumin Proteins 0.000 title claims abstract description 4
- 235000021241 α-lactalbumin Nutrition 0.000 title claims abstract description 4
- 235000018102 proteins Nutrition 0.000 title abstract description 4
- 102000004169 proteins and genes Human genes 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 title abstract description 4
- 235000007882 dietary composition Nutrition 0.000 title abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 title description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title description 4
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- -1 glutamine amino acid Chemical class 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 102000014777 Adipokines Human genes 0.000 description 4
- 108010078606 Adipokines Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000478 adipokine Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne une préparation diététique comprenant un mélange d'acides aminés, de vitamines et d'oligo-éléments pour la réduction de la masse grasse viscérale, la correction du dysfonctionnement du gras adiposopathe, la remise en route de la production de sérotonine pour la régulation de l'appétit, la réduction du stress oxydatif et la diminution de l'acidification sanguine.
Description
La présente. invention concerne une préparation diététique amaigrissante
et visant à combattre le syndrome métabolique du surpoids par l'action sur les adipokines et la fluidité membranaire.
Les produits diététiques traditionnels visent le seul amaigrissement des personnes en surpoids en tentant de conserver la masse maigre au détriment de la masse grasse.
Mais l'épidémie de surpoids fait apparaître une importante quantité de personnes en syndrome métabolique. Le syndrome se caractérise par un gras viscéral important (le tour de taille est supérieur à 90 cm pour les hommes et 80 cm pour les femmes), un taux de triglycérides sanguins au dessus de 1.5 g/1 et un indice de masse corporelle de 28. Le surpoids en lui-même n'est pas systématiquement dangereux pour la santé mais le syndrome métabolique conduit, dans la plus grande majorité des cas, aux maladies connexes: diabète de type II, cardiopathies et vasculopathies. Le gras viscéral caractérisant le syndrome métabolique n'est pas neutre car il libère des adipokines en particulier IL6 et TNF alpha qui sont hautement inflammatoires provocant la baise de l'hormone de régulation de l'appétit, l'adiponectine; de plus par un mécanisme, encore inconnu, le tryptophane circulant baisse et provoque la chute de l'hormone de la satiété : la sérotonine. D'autre part le stress oxydatif accompagnant le syndrome métabolique rigidifie la membrane des cellules provocant de l'insulino-résistance et Ieptino-résistance qui aggrave les conséquences morbides du surpoids.
L'invention se caractérise par la présence d'un mélange de protéines de lactosérum et/ou d'alpha-lactalbumine et/ou d'oeuf sur la base de 80 grammes par jour en traitement d'amaigrissement intense et de 30 grammes pour le maintien du poids; ce mélange se caractérisant par un contenu minimum de 6grammes de tryptophane et 6 grammes d'histidine; trois autres acides aminés sont ajoutés: glutamine de 3 à 6 grammes, la taurine de 0.5 à 3 grammes et d'arginine de 3 à 6 grammes, ensuite du magnésium pour 800 à 3 500mg, du calcium de 300 à 1 000 mg, du zinc de 20 à 40 mg, du chrome de 12 à 50}tg, de la vitamine B6 de 3 à 6 mg, de la vitamine B9 de 100 à 300 g, de la vitamine C de 100 à 300 mg, de la vitamine E de 25 à 50 mg, du bêta carotène de 5 à 20 mg.
Chaque composant a un objectif d'action précis caractérisant l'action spécifique du composé : 2 2875680 - réduction de la masse grasse viscérale mais aussi correction du dysfonctionnement du.gras adiposopathe par la réduction de l'inflammation des adipokines pour éliminer le risque cardiaque ( histidine), la diminution de l'insulino-résistance par l'action sur les adipokines ( histidine, zinc) et par la restauration de la fluidité membranaire (arginine, glutamine, taurine, zinc, chrome), l'augmentation de la sécrétion de l'adiponectine et enfin le rétablissement du contrôle de la distribution du gras par la leptine ( histidine).
- régulation de la satiété par la sérotonine (tryptophane, B6, Magnésium) - La régulation de l'appétit par une action instantanée (calcium) et à long terme à travers la leptine (histidine) et la régulation du glucagon like protéine 1(glutamine) - Diminution de l'acidification provoquée par les régimes protéinés (glutamine) - Diminution du stress oxydatif par les asti-oxydants (vitamine E, vitamine C, bêta carotène) pour aider à restaurer la fluidité membranaire en complément des composés spécifiques de cette fluidification (arginine, taurine, glutamine, chrome, zinc) 30 35
Claims (1)
1 Composé diététique, pour une dose journalière de 30 à 80 g,comprenant un mélange de protéines de lactosérum et/ou d'alpha lactalbumine et/ou d'oeuf caractérisé en ce qu'il comprend de plus, au moins 6 g de tryptophane et 6 g d'histidine 2 Composé diététique dans la revendication caractérisé en ce qu'il comprend, de plus, un acide aminé glutamine de 3 à 6 g, un acide aminé taurine de 0.5 à 3 g, un acide aminé arginine de 3 à 6 g par jour, 3 Composé diététique selon la revendication 2 caractérisé en ce qu'il comprend par ailleurs des minéraux et oligo-éléments: du magnésium pour 800 à 3 500 mg, du calcium de 300à 1 000 mg, du zinc de 20 à 40mg, du chrome de 12 à 15 g, des vitamines B6 de 3 à 6 mg, B9 de 100 à 300 g, C de 100 à 300 mg, E de 25 à 50 mg et bêta carotène de 5 à 20 mg
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0410312A FR2875680B1 (fr) | 2004-09-29 | 2004-09-29 | Compose dietetique pour combattre le syndrome metabolique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0410312A FR2875680B1 (fr) | 2004-09-29 | 2004-09-29 | Compose dietetique pour combattre le syndrome metabolique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2875680A1 true FR2875680A1 (fr) | 2006-03-31 |
| FR2875680B1 FR2875680B1 (fr) | 2010-08-20 |
Family
ID=36035952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0410312A Expired - Fee Related FR2875680B1 (fr) | 2004-09-29 | 2004-09-29 | Compose dietetique pour combattre le syndrome metabolique |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2875680B1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2900342A1 (fr) * | 2006-04-27 | 2007-11-02 | Cie Laitiere Europeenne | Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421309A2 (fr) * | 1989-10-02 | 1991-04-10 | SANDOZ NUTRITION Ltd. | Hydrolysates de protéines |
| FR2657013A1 (fr) * | 1990-01-18 | 1991-07-19 | Medgenix Group Sa | Composition dietetique a base de polypeptides et acides amines. |
| EP0747395A1 (fr) * | 1995-06-06 | 1996-12-11 | Clintec Nutrition Company, An Illinois Partnership | Composition pour le traitement de l'insuffisance rénale |
| FR2754181A1 (fr) * | 1996-10-03 | 1998-04-10 | Oenobiol S A Lab | Nouvelles utilisations de compositions a base d'alpha-lactalbumine |
| US6506422B1 (en) * | 1996-08-30 | 2003-01-14 | Nestec S.A. | Nutritional formula for phenylketonuria patients |
-
2004
- 2004-09-29 FR FR0410312A patent/FR2875680B1/fr not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421309A2 (fr) * | 1989-10-02 | 1991-04-10 | SANDOZ NUTRITION Ltd. | Hydrolysates de protéines |
| FR2657013A1 (fr) * | 1990-01-18 | 1991-07-19 | Medgenix Group Sa | Composition dietetique a base de polypeptides et acides amines. |
| EP0747395A1 (fr) * | 1995-06-06 | 1996-12-11 | Clintec Nutrition Company, An Illinois Partnership | Composition pour le traitement de l'insuffisance rénale |
| US6506422B1 (en) * | 1996-08-30 | 2003-01-14 | Nestec S.A. | Nutritional formula for phenylketonuria patients |
| FR2754181A1 (fr) * | 1996-10-03 | 1998-04-10 | Oenobiol S A Lab | Nouvelles utilisations de compositions a base d'alpha-lactalbumine |
Non-Patent Citations (3)
| Title |
|---|
| CANGIANO C ET AL: "Eating behaviour and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan", AMERICAN JOURNAL OF CLINICAL NUTRITION, AMERICAN SOCIETY FOR CLINICAL NUTRITION, BETHESDA, MD, US, vol. 56, 1 January 1992 (1992-01-01), pages 863 - 867, XP002444660, ISSN: 0002-9165 * |
| LUNVEN P ET AL: "Amino acid composition of hen's egg.", THE BRITISH JOURNAL OF NUTRITION, vol. 30, no. 2, September 1973 (1973-09-01), pages 189 - 194, XP002549115, ISSN: 0007-1145 * |
| ORTHEN-GAMBILL ET AL: "Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 31, no. 1, 1 September 1988 (1988-09-01), pages 81 - 86, XP022004663, ISSN: 0091-3057 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2900342A1 (fr) * | 2006-04-27 | 2007-11-02 | Cie Laitiere Europeenne | Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie |
| WO2007128901A1 (fr) * | 2006-04-27 | 2007-11-15 | Compagnie Laitiere Europeenne | Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie |
| AU2007247025B2 (en) * | 2006-04-27 | 2013-01-10 | Compagnie Laitiere Europeenne | Use of alpha-lactalbumin for regulation of glycemia |
| US8648039B2 (en) | 2006-04-27 | 2014-02-11 | Compagnie Laitiere Europeene | Use of alpha-lactalbumin for regulations of glycemia |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2875680B1 (fr) | 2010-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Katsanos et al. | A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly | |
| Torres et al. | Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders | |
| Näslund et al. | Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. | |
| Chartrand et al. | Influence of amino acids in dairy products on glucose homeostasis: the clinical evidence | |
| Cave et al. | Obesity, inflammation, and the potential application of pharmaconutrition | |
| Boirie | Physiopathological mechanism of sarcopenia | |
| Kiess et al. | Leptin, puberty and reproductive function: lessons from animal studies and observations in humans | |
| JP5002857B2 (ja) | Ｐｐａｒおよび／またはｐｐａｒ関連因子産生増強組成物 | |
| Beaudry et al. | Nutritional strategies to combat type 2 diabetes in aging adults: the importance of protein | |
| HUE032597T2 (en) | Nutritional composition for stimulating muscle protein synthesis | |
| JP2012533627A (ja) | 機能状態の喪失を減弱する方法 | |
| Bianchi et al. | Update on nutritional supplementation with branched-chain amino acids | |
| EP3313430A1 (fr) | Nouvelle utilisation thérapeutique de fgf19 | |
| Flynn et al. | Amino acids in health and endocrine function | |
| Sánchez-Jiménez et al. | IL-15 that a regulator of TNF-α in patients with diabetes mellitus type 2 | |
| Beck | Gastric inhibitory polypeptide: a gut hormone with anabolic functions | |
| Giglio et al. | Effects of whey protein supplementation on adiposity, body weight, and glycemic parameters: A synthesis of evidence | |
| SMITH et al. | Growth hormone in adults with protein-calorie malnutrition | |
| FR2875680A1 (fr) | Compose dietetique pour combattre le syndrome metabolique | |
| WO2015009225A1 (fr) | Produit à base d'une composition alimentaire | |
| Wetzler et al. | Intraperitoneal leptin modifies macronutrient choice in self-selecting rats | |
| EP2719291A1 (fr) | Produit dietetique destine a être administre a long terme aux personnes obeses operées en chirurgie bariatrique | |
| CA3216989A1 (fr) | Compositions nutritionnelles pour la conservation de la masse musculaire | |
| Gökbel et al. | Changes in serum leptin levels in strenuous exercise and its relation to zinc deficiency in rats | |
| Dunshea et al. | Effect of dietary protein on body composition and insulin resistance using a pig model of the child and adolescent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20060531 |
|
| RN | Application for restoration | ||
| FC | Decision of inpi director general to approve request for restoration | ||
| TP | Transmission of property | ||
| TP | Transmission of property |
Owner name: INTERNATIONAL NUTRITION RESEARCH COMPANY, LU Effective date: 20111027 |
|
| CL | Concession to grant licences |
Name of requester: LABORATOIRES NUTRITION ET CARDIOMETABOLISME, FR Effective date: 20140418 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |